Published in PLoS One on November 14, 2011
Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol (2014) 1.00
Human endogenous retroviruses and cancer: causality and therapeutic possibilities. World J Gastroenterol (2012) 0.88
Towards a vaccine to prevent cancer in Lynch syndrome patients. Fam Cancer (2013) 0.86
Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother (2016) 0.86
Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3' UTR. Proc Natl Acad Sci U S A (2014) 0.80
Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who? Oncoimmunology (2013) 0.76
Bilirubin and related tetrapyrroles inhibit food-borne mutagenesis: a mechanism for antigenotoxic action against a model epoxide. J Nat Prod (2013) 0.76
Viral infection causes a shift in the self peptide repertoire presented by human MHC class I molecules. Proteomics Clin Appl (2015) 0.76
Presentation of Cryptic Peptides by MHC Class I Is Enhanced by Inflammatory Stimuli. J Immunol (2016) 0.75
Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A (2016) 0.75
Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease. World J Gastroenterol (2015) 0.75
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64
Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res (2008) 1.81
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A (2001) 1.80
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol (2010) 1.73
Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer (2001) 1.53
Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol (2009) 1.48
The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes Cancer (2007) 1.40
Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells. Int J Cancer (2001) 1.23
MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem (2011) 1.13
Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol (2010) 1.12
Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun (2004) 1.12
Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability. PLoS One (2010) 1.12
Association of low-risk MSH3 and MSH2 variant alleles with Lynch syndrome: probability of synergistic effects. Int J Cancer (2011) 1.07
SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res (2009) 1.02
Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol (2003) 1.02
Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression. Cancer Res (2004) 1.02
A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother (2001) 1.00
Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Fam Cancer (2010) 0.98
Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability. BMC Cancer (2010) 0.93
In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. Histopathology (2009) 0.88
Genetic instability influences drug response in cancer cells. Curr Drug Targets (2010) 0.87
Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO). J Biomed Biotechnol (2010) 0.86
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64
Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer (2010) 1.14
Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol (2009) 1.14
Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun (2004) 1.12
Intracellular persisting Staphylococcus aureus is the major pathogen in recurrent tonsillitis. PLoS One (2010) 1.07
Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS One (2012) 1.06
Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS One (2012) 1.02
Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol (2003) 1.02
MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromosomes Cancer (2015) 0.97
Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers. Int J Cancer (2007) 0.97
Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. Eur J Hum Genet (2006) 0.94
Systems biologists seek fuller integration of systems biology approaches in new cancer research programs. Cancer Res (2009) 0.92
Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J (2011) 0.92
Impact of portal branch ligation on tissue regeneration, microcirculatory response and microarchitecture in portal blood-deprived and undeprived liver tissue. Microvasc Res (2011) 0.91
WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer (2004) 0.91
Prophylactic application of bovine colostrum ameliorates murine colitis via induction of immunoregulatory cells. J Nutr (2011) 0.90
COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther (2012) 0.89
Human endogenous retroviruses and cancer: causality and therapeutic possibilities. World J Gastroenterol (2012) 0.88
Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cell Immunol (2011) 0.86
Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer (2010) 0.86
Bacteriolytic therapy of experimental pancreatic carcinoma. World J Gastroenterol (2010) 0.85
Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes. Cancer Immunol Immunother (2011) 0.84
Tumor-infiltrating B cells: The ignored players in tumor immunology. Oncoimmunology (2012) 0.83
Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses. J Immunother (2008) 0.83
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison. PLoS One (2013) 0.83
Schistosoma mansoni infection but not egg antigen promotes recovery from colitis in outbred NMRI mice. Dig Dis Sci (2010) 0.82
Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine (2005) 0.82
Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells. Langenbecks Arch Surg (2010) 0.82
Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer (2005) 0.81
Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells. Int J Oncol (2011) 0.81
Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background. Cancer (2004) 0.81
The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol (2004) 0.80
The "North German Tumor Bank of Colorectal Cancer": status report after the first 2 years of support by the German Cancer Aid Foundation. Langenbecks Arch Surg (2013) 0.80
Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res (2013) 0.80
Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. Cancer Immunol Immunother (2013) 0.79
Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma. Pancreas (2007) 0.79
Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model. Eur Surg Res (2006) 0.79
Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. Eur J Cancer (2006) 0.78
cis-Hydroxyproline-mediated pancreatic carcinoma growth inhibition in mice. Int J Colorectal Dis (2010) 0.78
Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin. BMC Immunol (2013) 0.78
Combining bacterial-immunotherapy with therapeutic antibodies: a novel therapeutic concept. Vaccine (2012) 0.78
Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks. Clin Chem Lab Med (2015) 0.77
Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Exp Hematol (2010) 0.77
Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. J Cancer Res Clin Oncol (2013) 0.77
Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg (2011) 0.76
Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who? Oncoimmunology (2013) 0.76
CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions. Cancer Res (2002) 0.76
The impact of pyrvinium pamoate on colon cancer cell viability. Int J Colorectal Dis (2014) 0.76
A novel sialyl Le(X) expression score as a potential prognostic tool in colorectal cancer. World J Surg Oncol (2012) 0.76
Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol Ther (2015) 0.76
Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma. BMC Immunol (2011) 0.76
Bovine colostrum increases pore-forming claudin-2 protein expression but paradoxically not ion permeability possibly by a change of the intestinal cytokine milieu. PLoS One (2013) 0.76
NO counterbalances HO-1 overexpression-induced acceleration of hepatocyte proliferation in mice. Lab Invest (2007) 0.75
Semiallogenic fusions of MSI(+) tumor cells and activated B cells induce MSI-specific T cell responses. BMC Cancer (2011) 0.75
Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancer--a meta-analysis and current overview. Int J Colorectal Dis (2015) 0.75
The EpCAM high/CD44 high colorectal carcinoma stem cell phenotype is not preferentially expressed in tumour buds. Histopathology (2010) 0.75
Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. Int J Cancer (2002) 0.75
Microdensitometry of osteopontin as an immunohistochemical prognostic biomarker in colorectal carcinoma tissue microarrays: potential and limitations of the method in 'biomarker pathology'. Histopathology (2012) 0.75